Kao, Yung-ShuoYung-ShuoKaoLo, Chen-HsuChen-HsuLoYU-KANG TUHung, Cheng-HsienCheng-HsienHung2023-03-252023-03-252022-101396-0296https://www.scopus.com/inward/record.uri?eid=2-s2.0-85137224905&doi=10.1111%2fdth.15774&partnerID=40&md5=c585f03e0e55bcbfea35e14ba71150a2https://scholars.lib.ntu.edu.tw/handle/123456789/629673Capecitabine-induced hand-foot syndrome (HFS) is common in clinical practice. There are many regimens used to prevent HFS. However, the most effective preventive regimen has not yet been identified. Thus, we conducted a network meta-analysis to investigate the best preventive regimen for HFS. The PRISMA-NMA guidelines were used in this study. The PubMed, Cochrane, and Embase databases were searched. The main endpoint was set as HFS of National Cancer Institute grade 2 or more. We included only randomized control trials. The P-score was used to rank the regimens. Among all the regimens, topical silymarin had the best preventive ability compared with the placebo (OR: 0.08; 95% CI: 0.01-0.71). The other identified effective regimen included pyridoxine (400 mg) and celecoxib; compared with the placebo, the odds ratio was 0.27 (95% CI: 0.08-0.91) and 0.41 (95% CI: 0.18-0.95), respectively. Topical silymarin is the most useful regimen for preventing capecitabine-induced HFS.encapecitabine; chemotherapy; dermatitis; hand-foot syndrome; network meta-analysisjournal article10.1111/dth.15774360542632-s2.0-85137224905WOS:000847540600001https://api.elsevier.com/content/abstract/scopus_id/85137224905